SARS-COV-2 INFECTION and IT VACCINATION in AUTOINMUNE DISEASE-ASSOCIATED INTERSTICIAL LUNG DISEASE
Annals of the Rheumatic Diseases
; 81:1673, 2022.
Article
in English
| EMBASE | ID: covidwho-2008918
ABSTRACT
Background:
Intersticial lung disease (ILD) is a common condition in patients with systemic autoinmune diseases (SAI) that is characterized by increased morbility and mortality. Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has posed huge challenges worldwide and previous studies suggest that ILD patients experience a more severe clinical course.Objectives:
To analyze COVID-19 infection effects in patients with ILD associated systemic autoinmune disease (ILD-SAI) and to describe their vaccination status.Methods:
Design We performed a multicenter, retrospective, observational study from 6 teaching hospitals in Andalusia, Spain. Study protocol We included ILD-SAI patients rheumatoid arthritis (RA), systemic sclerosis (SS) and infam-matory myopathies (IM), assisted in reumatology consultations in 2021. Variables COVID-19 infection was the main variable that we collected and it was confrmed by a positive result on a PCR test. Secondary variables (1) COVID-19 severity defned as hospitalization or death;(2) vaccination status;(3) temporary relationship between infection and vaccination. Other variables included clinical, epidemiological characteristics, treatments received, type of ILD (UIP/NSIP), pulmonary function testing and high-resolution computed tomography. Statistic analysis Tw o multivariable logistic regression analysis to indentify the 'COVID-19' and 'severe COVID-19' associated factors.Results:
We included 176 ILD-SAI, of whom 105 (59.7%) had RA, 49 (27.8%) had SS and 22 (12.54%) had IM. The main baseline characteristics for the over-sall simple and te 3 subgroups are shown in Table 1. We recorded 22/179 (12.5%) SARS-CoV-2 infections, 7/22 (31.8%) of them were severe and 3/7 (42.85%) died. As to the vaccination, 163/176 (92.6%) patients received the complete dosis. Among those correctly vaccinated 18/163 (11%) had the SARS-CoV-2 infection, 4/18 (22.2%) after the vaccinated date and 14/18 (77.7%) when they still dint't have the complete vaccination. From the 13 not vaccinated patients, 4/13 (30.7%) had COVID-19. As to frequency, COVID-19 severity and vaccination, there were no difference between subgroups of CTD-ILD patients. The risk factors associated with the COVID-19 infection were the last FVC (OR [CI 95%], 0.971 [0.944-0.998];p=0.048), the vaccination (OR [CI 95%], 0.185 [0.049-0.691];p=0.012) and the Rituximab treatment(OR [CI 95%], 3.172 [1.028-6.785];p=0.045). Moreover, the only variable associated independently with the severe COVID-19 was the protective effect of vaccination (OR [CI 95%], 0.020 [0.003-0.119];p<0.001).Conclusion:
A total of 12.5% ILD-SAI patients were COVID-19 infected, most of them without the complete vaccine. Rituximab and a deterioration of FVC were risk factors for the COVID-19 wehreas the vaccination was a protective factor for the mild and severe infection.
rituximab; vaccine; adult; clinical article; conference abstract; consultation; controlled study; coronavirus disease 2019; deterioration; female; forced vital capacity; high resolution computer tomography; hospitalization; human; lung disease; lung function; male; multicenter study; muscle disease; observational study; retrospective study; rheumatoid arthritis; risk factor; Spain; systemic sclerosis; teaching hospital; vaccination; vaccinee
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Annals of the Rheumatic Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS